YIELD10 BIOSCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.11 USD | -10.97% |
|
-65.07% | -63.26% |
| May. 15 | Earnings Flash (YTEN) YIELD10 BIOSCIENCE Posts Q1 Revenue $300,000 | MT |
| May. 15 | Top Midday Decliners | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 2.25M | Sales 2025 * | 4M | Capitalization | 1.36M |
|---|---|---|---|---|---|
| Net income 2024 * | -11M | Net income 2025 * | -13M | EV / Sales 2024 * | 0.6 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.34 x |
| P/E ratio 2024 * |
-0.12
x | P/E ratio 2025 * |
-0.1
x | Employees | 29 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Yield10 Bioscience, Inc.
More recommendations
More press releases
| 1 day | -10.97% | ||
| 1 week | -65.07% | ||
| Current month | -62.73% | ||
| 1 month | -68.43% | ||
| 3 months | -68.92% | ||
| 6 months | -67.44% | ||
| Current year | -63.26% |
1 week
2.00
5.99
1 month
2.007.16
Current year
2.0017.26
1 year
2.0072.96
3 years
2.00242.40
5 years
2.001 228.80
10 years
2.0086 976.06
| Managers | Title | Age | Since |
|---|---|---|---|
Oliver Peoples
FOU | Founder | 66 | 92-05-31 |
Charles Haaser
DFI | Director of Finance/CFO | 68 | 07-12-31 |
Kristi Snell
CTO | Chief Tech/Sci/R&D Officer | 56 | 96-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 06-09-30 | |
Richard Hamilton
BRD | Director/Board Member | 61 | 17-03-01 |
Oliver Peoples
FOU | Founder | 66 | 92-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 2.11 | -10.97% | 27,521 |
| 24-05-16 | 2.37 | -17.71% | 116,511 |
| 24-05-15 | 2.88 | -45.25% | 384,071 |
| 24-05-14 | 5.26 | -1.87% | 43,920 |
| 24-05-13 | 5.36 | -11.26% | 74,281 |
Delayed Quote OTC Markets, May 17, 2024 at 03:59 pm EDT
More quotes
Yield10 Bioscience, Inc. is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa (Camelina) as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and PHA bioplastics for use as biodegradable bioplastics. The Company is pursuing Camelina seed oil products for two market opportunities and value chains. The first product is seed oil produced by Camelina, which is genetically engineered to enable production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA). The second product is Camelina seed oil for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD) and sustainable aviation fuel (SAF).
Calendar
2024-06-07
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
2.11
USD
Average target price
12
USD
Spread / Average Target
+468.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -63.26% | 1.36M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +28.31% | 12.16B | |
| +24.73% | 12.17B |
- Stock Market
- Equities
- YTEN Stock
